Overview

The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

The goal of the trial is to see if the Safety and Tolerability of X/T+X/T-EC combined with currently treated Lecanemab participants with Alzheimer's Disease compared with placebo. This is a 32 week study (4 weeks of screening,24 weeks of treatment and 4 weeks of safety follow up)

Phase:

PHASE2

Details

Lead Sponsor:

Neurology Office of South Florida

Collaborator:

Bristol-Myers Squibb

Treatments:

lecanemab